Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
May 16, 2024 14:00 ET
|
Tevogen Bio Inc
Former police chief & FBI National Academy graduate, William Keane, to work with functional leads, ensure policies, procure Tevogen’s lab space.
Immunology Collaboration and Licensing Agreements Analysis Report 2024 with Directory of Deals Signed Since 2016 - Company A-Z, Therapy Focus and Technology Type
May 16, 2024 10:45 ET
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Immunology Collaboration and...
Uveitis Treatment Market and Competitive Landscape Report, 2024: Analysis of Growth Opportunities by Drug Class, Disease Type, Distribution Channel, and Region to 2030
May 16, 2024 07:11 ET
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Uveitis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...
Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight - A USD 1.50 Billion+ Market Opportunity by 2030
May 14, 2024 08:50 ET
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering....
Immatics Announces First Quarter 2024 Financial Results and Business Update
May 14, 2024 07:00 ET
|
https://immatics.com/
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily...
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
May 13, 2024 16:47 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
May 08, 2024 11:00 ET
|
Siren Biotechnology, Inc.
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting
May 08, 2024 07:45 ET
|
Treos Bio Corp.
LONDON and BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said...
[Latest] Global Breast Cancer Therapeutics Market Size/Share Worth USD 66.1 Billion by 2033 at a 6.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 06, 2024 08:30 ET
|
Custom Market Insights
Austin, TX, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Breast Cancer Therapeutics Market Size, Trends and Insights By Type of Therapy...
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
April 18, 2024 08:30 ET
|
Imunon, Inc.
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter LAWRENCEVILLE, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc....